| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Global Perspective |
Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia 30329-4251
Introduction
When the ACS2 founded its intramural program of epidemiological research in 1946, lung cancer death rates in men had increased approximately 5-fold since 1930, the first year for which mortality statistics encompassed most of the United States (1) . Death rates from what had been the two leading fatal cancers in women, uterine (cervix and corpus combined) and stomach cancer, were decreasing, although lung cancer rates were just beginning to climb. Connecticut operated the only population-based tumor registry. Two activities that helped to ground the new program were collaborative efforts to improve the quality and availability of cancer surveillance data and the involvement of ACS volunteers in assembling large prospective cohort studies that could provide insights about cancer etiology. E. Cuyler Hammond, who first directed the program, saw in the rapidly expanding network of ACS volunteers an extraordinary human resource that could enroll and help to follow large prospective epidemiological cohorts.
More than 50 years later, intramural epidemiological research at ACS remains the most active epidemiological program based in a private, voluntary health organization. Cohort studies and cancer surveillance continue to be central to the program. This article will describe the mission and research activities of the current Department of Epidemiology and Surveillance Research. It will also direct readers toward a variety of publications and Web-based resources and describe opportunities and guidelines for training and/or collaborative research.
Mission
The overall mission of intramural epidemiological research at ACS is to conduct and publish original epidemiological research to advance our understanding of the occurrence, causes, and prevention of cancer. The two arms of the department, Surveillance Research and Analytic Epidemiology, also provide "service" to other parts of ACS and to the public. For example, Surveillance Research compiles and disseminates population-based statistics on cancer occurrence and prevention that are increasingly used to plan and evaluate state cancer control programs as well as for public education and advocacy. Because ACS is a voluntary, community-based organization, staff epidemiologists frequently translate epidemiological findings to nonepidemiological audiences including the media, cancer patients and their families, clinicians, basic researchers, volunteers, and other diverse constituencies. This important service, together with original research conducted by the department, helps to clarify exactly what research on disease patterns in human populations contributes to the understanding and control of cancer.
Roles of Surveillance Research
Currently, surveillance activities at ACS address three aspects of cancer: (a) occurrence (incidence, mortality, and survival); (b) prevention (prevalence statistics on risk factors and screening examinations); and (c) cancer patient care. The first two activities produce ACS educational publications, most of which are available electronically on the ACS website3 as well as from the divisional and national ACS offices. Surveillance Research publishes original studies that highlight disparities in cancer occurrence, risk factors, and prevention. These studies potentially speed the translation of existing knowledge into practice. The newest surveillance activity at ACS involves exploratory studies examining data needs and resources for monitoring of cancer patient care.
Cancer Occurrence.
ACS has published Cancer Facts and Figures annually since
1952. A similar document, Cancer Statistics, published
yearly since 1970 in CA—A Cancer Journal for
Clinicians, reaches a broader clinical audience and can be cited
in scientific papers (2)
. These reports disseminate
population-based data on cancer occurrence to the media, clinicians,
cancer researchers, and the public. Mortality statistics in these
publications are derived from state and national vital statistics
(1)
, from incidence and survival rates from the NCI
Surveillance, Epidemiology, and End Results program (3)
,
increasingly from state tumor registries, and from population
denominators from the United States Census. Unique to these
publications are ACS projections of the number of cancer cases and
deaths expected in each state and in the nation in the current year
(4)
. These projections are widely cited because they are
current, readily understood by the public, and reasonably accurate when
compared with the actual counts of cancer deaths tabulated several
years later. However, they represent projections rather than actual
counts. More detailed data on certain cancer sites are published
periodically in Breast Cancer Facts and Figures or in
expanded "banner" sections that discuss colorectal, prostate, and
childhood cancers in Cancer Facts and Figures. Most of these
are available through the ACS website3
under
"statistics archives."
Increasingly, ACS surveillance publications highlight inequities in the burden of cancer across socioeconomic, racial, and ethnic subgroups. Cancer Facts and Figures for African Americans (1998–1999) and a banner section on Racial and Ethnic Patterns published in 1997 describe the higher cancer occurrence rate and poorer survival rate in certain populations. These disparities have stimulated research on the interplay between socioeconomic and cultural factors, education, access to screening and health care, nutrition, and tobacco use.
Since 1998, ACS Surveillance Research has collaborated with the CDC, NCI, and the North American Association of Central Cancer Registries to publish an annual report on progress against cancer in the United States. These reports (5, 6, 7) characterize the decrease in incidence and mortality rates that has occurred for all cancers combined and for many specific cancer sites from 1990 through 1997. They also emphasize tobacco control and colorectal cancer screening as priority areas for cancer control. In 1998, ACS proposed challenge goals to the nation intended to stimulate additional actions to reduce cancer incidence and mortality and to improve the quality of life for cancer patients by the year 2015 (8) . Similar to the government’s Healthy People 2010 goals, these objectives aim to motivate progress in key areas of cancer prevention, early detection, and treatment.
Cancer Risk Factors and Screening.
In 1992, ACS began to compile and publish population-based
prevalence data on cancer risk factors and utilization of screening
tests to support state and national cancer control efforts. Two
resources are available for cancer control advocates and planners:
Cancer Prevention and Early Detection Facts and Figures is
published annually and archived data that can be formatted for
state-specific presentations are available on the ACS
website.3
These resources allow for comparisons of tobacco
use, nutrition (consumption of fruits and vegetables), physical
activity, obesity, and the utilization of screening tests for cancers
of the female breast, uterine cervix, and colorectum across states and
over time. Monitoring trends in youth and adult smoking, physical
inactivity, obesity, and under utilization of mammography, Pap, and
colorectal cancer screening provides immediate, objective feedback
about factors that affect cancer occurrence and/or progression.
Recognizing the need to address sun exposure behaviors among youth—a high-risk group for melanoma—ACS conducted a population-based survey of youth and their parents in 1998. This survey will provide national baseline measure of sun protection and sun exposure behaviors.4
Surveillance of Cancer Patient Care.
As an organization, ACS has long sought to improve the quality and
accessibility of cancer patient care. The Department of Epidemiology
and Surveillance Research began to grapple with the difficult
challenges of cancer patient care surveillance in 1996. The Institute
of Medicine has underscored the need for reliable, population-based
data on the diagnostic and treatment services provided to cancer
patients (9)
. This need is accentuated by the rapid
changes in medical delivery systems, increasing health care costs,
aging of the population, disparities in access to quality health care,
and uncertainties about whether research advances are translated into
practice. Equally daunting, however, are the obstacles to collecting
such information. These include the multiplicity of providers, the cost
of actively collecting data from many sources, organizational
jurisdiction, issues of patient confidentiality, and the need to
interview patients directly to verify that recommended treatment was
received. In 1999, Surveillance Research collaborated with three state
cancer registries and the American College of Surgeons to examine the
feasibility of conducting population-based patterns of care studies and
to estimate the proportion of patients who received the recommended
treatment for colon cancer. Groups that are collaborating to develop
cancer patient care surveillance include the ACS, the American College
of Surgeons, the CDC, the NCI, and the North American Association of
Central Cancer Registries.
Roles of Analytic Epidemiology
Since the 1950s, the intramural epidemiology program at ACS has assembled and followed very large cohorts to provide insights about cancer etiology and prevention. The three main cohorts, Hammond-Horn and the CPS-I and CPS-II described below, feature prominently in many Surgeon General Reports on tobacco (10, 11, 12, 13) . The traditional prospective cohort studies remain the foundation of analytic epidemiological research at ACS; methods are being updated to include the collection of biological samples and enhanced information on lifestyle, medical, nutritional, and other environmental factors that may interact with familial or acquired genetic susceptibility. This section will describe: (a) the original ACS cohorts initiated before 1990; (b) two new resources, the CPS-II Nutrition and LifeLink cohorts, which will soon provide biological samples, more extensive questionnaire information, and ascertainment of incident cancers as well as deaths; and (c) past and current examples of collaborative research.
ACS Cohorts Before 1990.
The first ACS cohort study was Hammond-Horn (Table 1)
, initiated in 1952 to measure death rates from lung cancer, heart
disease, and other conditions in relation to tobacco smoking among
almost 188,000 white men, ages 50–69 years, residing in nine states
(14, 15, 16)
. Together with E. Cuyler Hammond, Daniel Horn,
and other ACS staff, 22,000 community volunteers recruited their male
acquaintances to complete a confidential, short questionnaire. Each
year during the 44 months of follow-up, the volunteers recontacted the
people they had enrolled to determine vital status. Aspects of
Hammond-Horn became the prototype for subsequent ACS cohorts, with
large numbers of community volunteers recruiting study participants and
then helping to identify deaths during follow-up.
|
The next two CPSs, CPS-I and CPS-II, followed the general Hammond-Horn
model but were over five times larger, included women as well as men,
encompassed more states, and extended the duration of follow-up (Table 1)
. CPS-I included approximately one million men and women recruited in
1959 by 68,000 volunteers in 25 states (21
, 22)
. The
entire CPS-I cohort was followed for 12 years, through 1972, with
longer follow-up of subcohorts from California and long-term survivors
(the latter are not shown in Table 1
). CPS-II began in 1982 under the
direction of Larry Garfinkel and encompassed nearly 1.2 million
subjects recruited by 77,000 volunteers in 50 states, the District of
Columbia, and Puerto Rico [Table 1
(23
, 24)
]. Mortality
follow-up of the entire CPS-II cohort is complete through 1998 and
continues through biennial linkage with the National Death Index
(25)
. In both cohorts, enrollment was restricted to adults
age 30 years or older to reduce the costs of following a younger cohort
for mortality. The actual questionnaires used in CPS-I, CPS-II, and all
subsequent cohorts will soon be available on the ACS
website.3
The massive ACS cohorts have been particularly valuable in tobacco research because of their size, prospective design, and use of comparable methods to select and follow successive generations of Americans with regard to smoking and mortality (26, 27, 28, 29, 30) . CPS-I demonstrated that the sharply increasing lung cancer death rates among United States women from 1959 through 1972 occurred only among smokers (21 , 22) . CPS-II is the largest contemporary study of tobacco and mortality. The over 480,000 lifelong nonsmokers in CPS-II provide the most stable current estimates of lung cancer risk in the absence of active smoking. Relative risk estimates from CPS-II are used by the CDC to estimate deaths attributable to smoking in the United States (31) and the Americas (32) . CPS-II data were also used in a collaboration with Peto et al. (33) to estimate deaths from smoking in 50 developed countries.
Besides contributing to tobacco research, the baseline CPS-II cohort has provided important insights about how lifestyle factors such as obesity, alcohol consumption, medications and hormones, reproductive factors, and familial and personal medical conditions affect cancer and other chronic diseases. CPS-II data attracted widespread research attention and funding to the potential of aspirin-like drugs to inhibit colorectal cancer (34 , 35) . Approximately nine publications from CPS-II have examined the relationship between hormones in women and mortality from cancers of the colon, breast, and ovary (36, 37, 38, 39, 40, 41, 42, 43) .5 A publication on obesity and mortality showed that among both men and women in CPS-II, the optimal range of body mass index remains constant throughout life, rather than increasing with age (44) . Medical conditions associated with increased risk of various cancers include diabetes [pancreas and colon cancer (45) ],6 infertility [ovarian cancer (46) ], nonmelanoma skin cancer [other fatal cancers (47) ], and hypertension or antihypertensive medications [renal cell carcinoma (48) ] but not spontaneous abortion [breast cancer (49) ]. A 1995 analysis of air pollution and mortality found increased death rates among CPS-II participants living in cities with higher particulate air pollution (50) . Together with the Harvard Six Cities Study (51) , CPS-II findings (50) motivated the Environmental Protection Agency to propose more stringent limits on particulate air pollution. A complete list of publications from CPS-II and other ACS cohorts will soon be available on the ACS website.3
The potential contribution of large cohort studies to the fields of
molecular and genetic cancer research can be illustrated by two
particular insights from CPS-II. Table 2
shows that with respect to death from lung cancer, women are not more
likely than men to die from lung cancer after equivalent cigarette
smoking. Within narrow strata of age, years of smoking, and cigarettes
per day, women have similar or lower death rates from lung cancer than
men. This is consistent with several other large prospective studies
that show no sex difference in the risk of lung cancer from smoking
(52, 53, 54)
. The higher relative risk estimates among women
than men reported by several case-control studies are more likely to
reflect biased estimates of exposure in case-control studies, as well
as possibly the lower background lung cancer risk in older women than
in men who have never smoked actively (54, 55, 56, 57)
. Better
evidence is needed to establish the hypothesis of greater risk in women
before biochemical and mechanistic studies examine why it occurs
(58)
.
|
is that lung cancer death rates among
smokers increase so rapidly with the duration of smoking that studies
examining genetic polymorphisms must control more rigorously for
smoking parameters than simply considering smoking status (current,
former, or never) or pack-years. In CPS-II, as in the British Doctors
Study (59)
, lung cancer mortality increases with the
fourth or fifth power of the duration of smoking and with approximately
the second power of the number of cigarettes smoked per day. Molecular
studies that do not stratify finely on years of smoking and cigarettes
per day (60, 61, 62)
are vulnerable to residual confounding.
CPS-II Nutrition Cohort.
The CPS-II Nutrition Cohort was established as a subgroup of the larger
CPS-II (Table 1)
in 1992–1993, several years after the ACS Home Office
moved from New York to Atlanta, and Dr. Clark Heath succeeded Larry
Garfinkel as department head. The two objectives of the Nutrition
Survey were (a) to obtain current, more detailed information
on diet, physical activity, adiposity, and other factors that were
either inadequately measured or subject to change since 1982 and
(b) to initiate prospective follow-up of incident cancers as
well as deaths. A self-administered, 10-page questionnaire was mailed
to approximately 516,000 CPS-II men and women, ages 50–74 years, who
resided in 21 states with population-based state cancer registries.
These states included California, Connecticut, Florida, Georgia,
Illinois, Iowa, Louisiana, Maryland, Massachusetts, Michigan,
Minnesota, Missouri, New Mexico, New Jersey, New York, North Carolina,
Pennsylvania, Utah, Virginia, Washington, and Wisconsin. This target
population was originally chosen to enable follow-up of cancer
incidence using computerized linkage with state cancer registries.
Characteristics of the 184,194 men and women who completed the
1992/1993 Nutrition Survey and were thus enrolled in the CPS-II
Nutrition Cohort are shown in Table 1
. Respondents include a smaller
percentage of non-whites, current smokers, and persons with less than a
college education than the baseline CPS-II cohort. Additional
questionnaires were mailed to the Nutrition subgroup in 1997/1998 and
1999/2000 and will continue biennially to update information on
self-reported cancer and to obtain additional exposure data. Because of
the age of the cohort, new cancer cases accrue rapidly: 10,775 new
cases were reported in the interval between 1992/1993 and 1997/1998
(Table 3)
. A pilot linkage study with 11 cancer registries verified
self-reported cancer of all sites combined against tumor registry
records with high sensitivity (0.92–0.97) and a low percentage of
false positives [specificity > 0.99 (63)
]. Based
on this pilot work, we now identify incident cancers by contacting
participants who report a new cancer on the biennial questionnaire and
by requesting permission to verify and augment the diagnostic
information with medical records. Computerized linkage with state
cancer registries is used as needed to supplement verification of
self-reported incident cancers.
|
CPS-II LifeLink Cohort.
The CPS-II LifeLink Cohort was initiated in 1998 with the goal of
collecting and storing blood samples from approximately 40,000 members
of the Nutrition Cohort (Table 1)
. Potential blood donors include the
approximately 134,000 surviving members of the Nutrition Cohort who
live in urban and suburban areas. Cohort members receive an invitation
by mail. Those who indicate willingness to donate blood are scheduled
for an appointment at a nearby hospital approved by the American
College of Surgeons, Commission on Cancer. A maximum of 43 ml of whole
blood is drawn in two 15-ml tubes containing the anticoagulant EDTA and
a 13-ml serum separator tube. The serum separator tubes are centrifuged
to separate serum from cellular blood components before transport.
Samples are chilled and then shipped in foam containers with coolant
packs by express mail to a central repository. There the specimens are
divided into aliquots (Fig. 1)
and stored in liquid nitrogen (vapor phase). Aliquots of pooled blood
from healthy volunteers are interspersed with the participant samples
for use in future quality control assessment. We expect blood
collection and storage to be completed in early 2001. A second proposal
is under review to collect buccal cell DNA from mouthwash samples from
at least 50,000 Nutrition Cohort members who did not give blood.
|
To oversee this valuable resource, ACS will form a standing review panel comprised of intra- and extramural scientists, epidemiologists familiar with large cohort studies, and laboratory and other researchers who collaborate on studies that integrate cancer epidemiology, biology, genetics, and laboratory research. The precise questions to be addressed in LifeLink will depend on the scientific issues that are most relevant at the time, improvements in laboratory technology to study these issues, and the proposals that are judged to have the greatest scientific merit and largest implications for cancer research and/or control. Priority will be given to study proposals of high scientific merit that are best addressed prospectively and that test promising hypotheses rather than generate them. Approved proposals will be further developed and submitted as grant applications to the NIH or other funding agencies.
Collaborative Research.
Historically, ACS intramural epidemiology research has greatly expanded
its scientific contributions through multidisciplinary extramural
collaborations. One series of collaborations involved autopsy studies,
unrelated to CPS-I or CPS-II, with Dr. Oscar Auerbach, a research
pathologist in New Jersey (67, 68, 69, 70, 71, 72, 73, 74)
. These studies helped
to demystify the carcinogenic effects of tobacco by demonstrating
widespread phenotypic changes (also called a "field" effect) and a
continuum of injury from precancerous changes to invasive cancers in
the lung (67)
and other organs (67, 68, 69, 70, 71, 72, 73, 74)
,
correlating closely with the amount and duration of smoking. This
spectrum of injury was seen in tissues exposed directly [larynx,
bronchi, and lung (68, 69, 70, 71, 72)
] or indirectly (bladder,
esophagus, and pancreas) to carcinogens in tobacco smoke (73
, 74)
. Some 2000 tissue specimens (paraffin blocks) from over 1300
patients in the Auerbach studies have been saved in an archive that is
still available for collaborative studies (75)
. Another
historic collaboration with Dr. Irving Selikoff involved studies of
lung cancer in asbestos-exposed insulation workers (76)
.
Currently, ACS epidemiologists collaborate extensively with extramural researchers. Ongoing collaborative studies with researchers at the CDC involve studies of tobacco, nutrition, obesity, and diabetes in relation to specific cancers. Collaborative studies with university researchers include ongoing studies of tobacco and hormones with Oxford University, studies of nutrition and air pollution with Harvard University, and studies of the economic implications of tobacco control policies with Duke University and Massachusetts Institute of Technology.
ACS is also participating in a NCI initiative to form a Consortium of Cohort Studies sufficiently large to address interactions between genetic factors and environmental exposures. Typically, several thousand cases are needed to provide statistically stable estimates of gene-environment or gene-gene-environment interactions. The current ACS proposal to collect buccal cell DNA from participants who have not already given blood in the CPS-II Nutrition Survey is motivated by the very large sample size needed to study interactions between environmental factors and genetic susceptibility.
Proposals to collaborate using the currently available questionnaire data are evaluated with regard to their scientific merit, timeliness, relevance to cancer, the suitability of ACS data to address the research question, and the likely productivity and collegiality of the working relationship. The mutual benefit of such collaborations is enhanced when the researchers can complete much of the research at the ACS Home Office in Atlanta and/or bring expertise that would otherwise not be available to the department. Funding for collaborative projects is generally sought either through external grants or by ACS fellowship support for visiting scientists. The department also provides several opportunities for training, career development, and/or sabbaticals through its fellowship program. Further information can be obtained by contacting Dr. Michael J. Thun, who succeeded Dr. Clark Heath as department head in 1998.
Research Opportunities
A major strength of the ACS cohort studies, historically, has been their size. Size remains critical for providing stable risk estimates in important subgroups of the CPS-II population such as the more than 480,000 lifelong nonsmokers and 52,000 African Americans. Size is also critical in measuring dose-response gradients over a wide range of exposure and in studying cancer end points of intermediate frequency. The age distribution of CPS-I and CPS-II allows certain cancer hypotheses to be tested more rapidly with greater statistical precision than is possible in younger, smaller cohorts. Participants are also more heterogeneous with regard to education and socioeconomic status than are health professionals in the Harvard cohort studies. Parallel analyses of certain hypotheses can be conducted in men and women, in African Americans and whites, and in various educational and occupational subgroups.
Another strength of the ACS cohorts is that comparisons between CPS-I and CPS-II provide an unusual longitudinal perspective on how mortality from tobacco smoking has changed over the last half-century in the United States. Valid comparisons are possible because both cohort studies used similar methods of selection, exposure ascertainment, and follow-up to measure tobacco smoking and mortality over several generations. The potential for longitudinal comparisons has been extended in the CPS-II Nutrition Survey, which collects more detailed and periodically updated information on nutrition, physical activity, weight and weight change, and medical screening. Future cohort studies can examine how ongoing changes in nutrition, other health-related behaviors, tobacco use, and medical care influence subsequent patterns of morbidity and mortality.
Conclusions
Over the last 50 years, the extraordinary progress in understanding cancer biology and in identifying many of the important "environmental" causes of cancer has often outstripped our ability to implement this knowledge equitably and effectively in controlling cancer. At the same time, advances in molecular biology and genetics are providing powerful new tools with which to understand the progressive development of cancer and the interplay between "environmental" causes of cancer and genetic factors that affect individual susceptibility. The Epidemiology and Surveillance Research program at ACS has a remarkable opportunity to address both of these challenges. By monitoring the occurrence of cancer and temporal trends in risk factors, social policies, and medical practices that affect cancer, Surveillance Research can accelerate the application of existing knowledge into practice. Analytic Epidemiology, in turn, can develop the potential of cohort studies to measure "environmental" exposures, to understand the interplay between these and genetic factors that affect individual susceptibility, and to translate this knowledge into applications that improve public health.
Acknowledgments
We acknowledge the hundreds of thousands of ACS volunteers whose trust and goodwill make epidemiological research at ACS possible, and who provide much of the satisfaction and focus to the work. We also thank the Illinois Division for generous support of the CPS-II Nutrition and LifeLink Cohorts.
Footnotes
1 To whom requests for reprints should be
addressed, at Department of Epidemiology and Surveillance Research,
American Cancer Society, National Home Office, 1599 Clifton Road NE,
Atlanta, GA 30329-4251. Phone: (404) 329-5747; Fax: (404) 327-6450;
E-mail: mthun{at}cancer.org 
2 The abbreviations used are: ACS, American Cancer
Society; NCI, National Cancer Institute; CDC, Centers for Disease
Control and Prevention; CPS, Cancer Prevention Study.
3 Internet address: http://www.cancer.org.
4 V. E. Cokkinides, K. Johnston-Davis, M.
Weinstock, M. O’Connell, W. Kalsbeek, M. J. Thun, and P. A. Wingo. Sun
exposure and sun protection behaviors and attitudes in U.S. youth, 11
to 18 years old, submitted for publication.
5 C. Rodriguez, E. E. Calle, A. V.
Patel, L. M. Tatham, E. J. Jacobs, and M. J. Thun. The
effect of body mass on the association between estrogen replacement
therapy and mortality among elderly United States women. Am. J.
Epidemiol., in press, 2000.
6 S. S. Coughlin, E. E. Calle, A. V. Patel, and M. J. Thun. Predictors of pancreatic cancer
mortality among a large cohort of United States adults, submitted for
publication.
Received 3/15/00; revised 6/21/00; accepted 6/28/00.
References
This article has been cited by other articles:
|
|
 |
|
  S J. Henley, C. J Connell, P. Richter, C. Husten, T. Pechacek, E. E Calle, and M. J Thun Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco Tob. Control, February 1, 2007; 16(1): 22 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A M Dozier, D J Ossip-Klein, S Diaz, N P Chin, E Sierra, Z Quinones, T D Dye, S McIntosh, and L Armstrong Tobacco use in the Dominican Republic: understanding the culture first Tob. Control, June 1, 2006; 15(suppl_1): i30 - i36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, D. Burns, A. Jemal, T. G. Shanks, and E. E. Calle Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst, May 17, 2006; 98(10): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Weisskopf, M. L. McCullough, N. Morozova, E. E. Calle, M. J. Thun, and A. Ascherio Prospective Study of Occupation and Amyotrophic Lateral Sclerosis Mortality Am. J. Epidemiol., December 15, 2005; 162(12): 1146 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. McCullough, H. S. Feigelson, W. R. Diver, A. V. Patel, M. J. Thun, and E. E. Calle Risk Factors for Fatal Breast Cancer in African-American Women and White Women in a Large US Prospective Cohort Am. J. Epidemiol., October 15, 2005; 162(8): 734 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, M. J. Thun, M. Cudkowicz, and A. Ascherio Prospective study of military service and mortality from ALS Neurology, January 11, 2005; 64(1): 32 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ascherio, M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, C. Rodriguez, and M. J. Thun Coffee Consumption, Gender, and Parkinson's Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen Am. J. Epidemiol., November 15, 2004; 160(10): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Weisskopf, M. L. McCullough, E. E. Calle, M. J. Thun, M. Cudkowicz, and A. Ascherio Prospective Study of Cigarette Smoking and Amyotrophic Lateral Sclerosis Am. J. Epidemiol., July 1, 2004; 160(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Henley, M. J. Thun, A. Chao, and E. E. Calle Association Between Exclusive Pipe Smoking and Mortality From Cancer and Other Diseases J Natl Cancer Inst, June 2, 2004; 96(11): 853 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Harris, M. J Thun, A. M Mondul, and E. E Calle Cigarette tar yields in relation to mortality from lung cancer in the cancer prevention study II prospective cohort, 1982-8 BMJ, January 10, 2004; 328(7431): 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Bach, M. W. Kattan, M. D. Thornquist, M. G. Kris, R. C. Tate, M. J. Barnett, L. J. Hsieh, and C. B. Begg Variations in Lung Cancer Risk Among Smokers J Natl Cancer Inst, March 19, 2003; 95(6): 470 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Bach and D. Schrag Re: Risk Charts: Putting Cancer in Context J Natl Cancer Inst, October 16, 2002; 94(20): 1584 - 1585. [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Taylor Jr, V. Hasselblad, S. J. Henley, M. J. Thun, and F. A. Sloan Benefits of Smoking Cessation for Longevity Am J Public Health, June 1, 2002; 92(6): 990 - 996. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
